Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07093710RecruitingPhase 1/Phase 2
Golidocitinib combo for relapsed peripheral T-cell lymphoma
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
Guangzhou, GuangdongAges 18 years+ - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Greenville, North CarolinaAges 18–80 - NCT07095075RecruitingEarly Phase 1
LUCAR-DKS1 for severe autoimmune diseases
This early-phase trial tests an experimental treatment called LUCAR-DKS1, which uses your own immune cells to target and control severe autoimmune diseases like lupus, vasculitis, and scleroderma that haven't responded to other treatments.
Bengbu, AnhuiAges 18–70 - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+ - NCT07096700Recruiting
VR and wearable brace for multiple sclerosis rehabilitation
This trial tests whether combining virtual reality exercises with a leg brace can help people with multiple sclerosis improve their walking and balance. If you have mild to moderate disability and can use the Exoband brace, you may be eligible.
Bologna, BolognaAges 18–65 - NCT07097207RecruitingPhase 1/Phase 2
Study of CD19CD20-CAR-T for B-cell lymphoma
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07097805Recruiting
GLITTER: Improving blood sugar with team, tech, and support
This study tests whether a team approach—including technology, education, and support from peers—can help people with type 1 diabetes improve their blood sugar levels. It may be a good fit if you have type 1 diabetes and are looking for extra help managing it.
Beijing, Beijing MunicipalityAges Any age - NCT07097818Recruiting
GLITTER Study: Better Blood Sugar Control in Type 1 Diabetes
This study tests a program to help people with type 1 diabetes improve their blood sugar control using continuous glucose monitors, insulin pumps, and education sessions. It includes remote monitoring and camp activities for some participants.
Beijing, Beijing MunicipalityAges 6 years+ - NCT07098364RecruitingPhase 1/Phase 2
ST-067 with CAR T-cell therapy for large B-cell lymphoma
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT07098403RecruitingPhase 3
Study of SHR-1905 for severe uncontrolled asthma
This trial tests an experimental drug called SHR-1905 for people with severe asthma that is not well controlled by their current treatments. The study aims to see if the drug can reduce asthma attacks and improve breathing.
Guangzhou, GuangdongAges 18 years+ - NCT07099391RecruitingPhase 1/Phase 2
Study of two drug combos for newly diagnosed multiple myeloma
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
Basking Ridge, New JerseyAges 18 years+ - NCT07099443Recruiting
How BTK Degraders Work in CLL
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
AngersAges 18 years+ - NCT07100067Recruiting
LCAR-F33S for Relapsed/Refractory Multiple Myeloma
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
BeijingAges 18 years+ - NCT07100873RecruitingPhase 1
Testing a new drug for rheumatoid arthritis
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07101445RecruitingPhase 4
Comparing steroids to prevent reactions to motixafortide in multiple myeloma
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT07102030Recruiting
Understanding lupus subgroups to improve treatment
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
StockholmAges 18–100 - NCT07103512Recruiting
Scalene hold-relax therapy plus standard physical therapy for asthma
This study tests whether adding a gentle muscle-relaxation technique for neck muscles to standard physical therapy can help people with allergic asthma breathe easier.
Mānsehra, Khyber PkahtoonKhwaAges 22–44 - NCT07104058Recruiting
FAPI PET scan to predict relapse in IgG4-RD
This study tests whether a special PET scan (FAPI PET/CT) can detect tiny signs of disease activity (MRD) in people with stable IgG4-RD, and whether it helps predict who might relapse.
Beijing, Beijing MunicipalityAges 18–75 - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07105059RecruitingPhase 1
Teclistamab and mezigdomide for multiple myeloma
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
Basking Ridge, New JerseyAges 18 years+ - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.